Meta-analysis of Cohort Studies on Clinical Efficacy of Icodextrin Peritoneal Dialysate  

作　　者：Ren Hongyan Wang Yaoling Hui Xu Li Xue Zhao Kun Huang Zhe 

机构地区：[1]School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China [2]China National Health Develo-pment Research Center,Beijing 100000,China [3]School of Business Health,Lanzhou University,Lanzhou 730000,China

出　　处：《Asian Journal of Social Pharmacy》2024年第3期279-290,共12页亚洲社会药学（英文）

摘　　要：Objective To evaluate the effect of real-world practices for icodextrin peritoneal dialysis solution on patients with end-stage renal disease(ESRD)by Meta-analysis.Methods The PubMed and Embase databases were systematically searched for real-world research literature on icodextrin peritoneal dialysate in the treatment of ESRD patients,and RevMan5.4 statistical software was used for Meta-analysis.Results and Conclusion 12 studies with 114656 patients were included.Meta-analysis results showed that icodextrin peritoneal dialysis had good effects on mortality[RR=0.72,95%CI(0.62,0.83),P<0.001],congestive heart failure[RR=0.67,95%CI(0.52,0.87),P=0.003],and risk of new-onset diabetes[RR=0.65,95%CI(0.49,0.86),P=0.003],which was consistent with the Meta-analysis based on clinical trials.Meanwhile,there was no significant difference in PD technical failure rate[RR=0.67,95%CI(0.44,1.00),P=0.05],peritonitis[RR=1.02,95%CI(0.99,1.05),P=0.14],cardiovascular and cerebrovascular diseases[RR=0.79,95%CI(0.59,1.05),P=0.10],coronary artery disease[RR=0.99,95%CI(0.92,1.07),P=0.80],stroke[RR=0.86,95%CI(0.66,1.10),P=0.23],and atrial fibrillation[RR=0.73,95%CI(0.37,1.44),P=0.36].However,it might increase the risk of hypertension[RR=1.05,95%CI(1.03,1.07),P<0.001].Therefore,icodextrin can effectively reduce the risk of mortality,congestive heart failure,and new-onset diabetes,which is beneficial to ESRD patients.

关 键 词：icodextrin peritoneal dialysis fluid peritoneal dialysis end-stage renal disease MORTALITY META-ANALYSIS 

分 类 号：R57[医药卫生—消化系统]